Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms, Head and Neck: full-pipeline trial registry
1 of 5 indexed Neoplasms, Head and Neck trials are currently recruiting.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Neoplasms, Head and Neck: 5 US clinical trials tracked, 1 recruiting.
Neoplasms, Head and Neck is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 3 of these trials.
Enrollment posture brief
Registry condition neoplasms-head-and-neck
OPEN 1 | RECR 20% | LATE 2 | EARLY 3 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Neoplasms, Head and Neck lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms, Head and Neck on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms, Head and Neck is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neoplasms, Head and Neck research.
GlaxoSmithKline accounts for 3 of 5 trials (60%). 2 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasms, Head and Neck enrolment sits around 316 participants.
Median target enrolment is 316 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Neoplasms, Head and Neck research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
GlaxoSmithKline
NCT06256588
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
PDS Biotechnology
NCT06790966
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
NCT06062420
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
PDS Biotechnology
NCT04260126
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
GlaxoSmithKline
NCT00725764
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms, Head and Neck records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms, Head and Neck trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms, Head and Neck page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Neoplasms, Head and Neck trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Neoplasms, Head and Neck trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms, Head and Neck condition card totals 5 registered trials; most-linked intervention Dostarlimab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.